Standard and innovative treatments for systemic lupus erythematosus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This literature review describes the standard methods of therapy for systemic lupus erythematosus, which remain valid, including glucocorticosteroids, cytostatic and aminoquinoline drugs. The prospects of innovative treatment methods are discussed: anti B-cell therapy; the use of inhibitors of interferon, JAK-STAT and pro-inflammatory cytokines.

Full Text

Restricted Access

About the authors

E. A Aseeva

V.A. Nasonova Research Institute of Rheumatology

Email: eaasseeva@mail.ru

S. K Soloviev

Clinical Diagnostic Center MEDSI

N. Yu Nikishina

Clinical Diagnostic Center MEDSI

E. L Nasonov

V.A. Nasonova Research Institute of Rheumatology

A. M Lila

V.A. Nasonova Research Institute of Rheumatology

References

  1. Michelson H. The problem of lupus erythematosus. Calif Med. 1949;70(1):5-9.Hench PS., Kendall E.C., Slocumb CH., Polley H.F. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions: A study in clinical physiology, Arch Int Med. 1950;85(4):545-666. doi: 10.1001/archinte.1950.00230100002001.
  2. Насонов Е.Л., Российские клинические рекомендации. Ревматология М., 2017. 464 с
  3. Wallace D.J. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol 2015;11:616-20. doi: 10.1038/nrrheum.2015.86
  4. Mosca M., Tani C., Carli L., et al. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol. 2011;29(5 Suppl. 68):S126-29.
  5. Apostolopoulos D., Morand E.F. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatol. (Oxford). 2017;56(Suppl. 1):i114-22. doi: 10.1093/rheumatology/kew406.
  6. Fanouriakis A., Kostopoulou M., Alunno A., et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. Doi: 10.1136/ annrheumdis-2019-215089.
  7. Gladman D.D., Urowitz M.B., Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1955-59.
  8. Zonana-Nacach A., Barr S.G., Magder L.S., et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthr Rheum. 2000;43:1801-808. doi: 10.1002/1529-0131(200008)43:8<1801:: AID-ANR16>3.0.C0;2-0.
  9. Dixon W.G., Abrahamowicz M., Beauchamp M.-E., et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012;71:1128-33. Doi: 10.1136/ annrheumdis-2011-200702.
  10. Bruce I.N. 'Not only.. but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatol. 2005;44:1492-502. Doi: 10.1093/ rheumatology/kei142.
  11. Bhangle S.D., Kramer N., Rosenstein E.D. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013;33:1923-32. doi: 10.1007/s00296-013-2750-z.
  12. Carter E.E., Barr S.G., Clarke A.E. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. doi: 10.1038/nrrheum.2016.137.
  13. Barber M.R.W, Clarke A.E. Socioeconomic consequences of systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29(5):480-85. doi: 10.1097/ B0R.0000000000000416.
  14. van Vollenhoven R.F., Mosca M., Bertsias G., et al. Treat-to-target in systemic lupus rythematosus: recommendations from an international Task Force. Ann Rheum Dis. 2014;73:958-67. Doi:10.1136/ annrheumdis-2013-205139.
  15. Соловьев С.К., Асеева Е.А., Зоткин Е.Г. и др. Проблемы низкой активности и ремиссии при системной красной волчанке Научно-практическая ревматология. 2019;57(2):218-21. [Soloviev S.K., Aseeva E.A., Zotkin E.G., et al. Problems of low activity and remission in systemic lupus erythematosus Nauchno-prakticheskaya revmatologiya. 2019;57(2):218-21. (In Russ.)].
  16. Соловьев С.К., Асеева Е.А., Насонов Е.Л. и др. Возможности и перспективы отмены глюкокортикои-дов при системной красной волчанке. Современная ревматология. 2020;14(1):6-11. [Soloviev S.K., Aseeva E.A., Nasonov E.L., et al. Possibilities and prospects of glucocorticoid withdrawal in systemic lupus erythematosus. Sovremennaya revmatologiya. 2020;14(1):6-11. (In Russ.)].
  17. Durcan L., O'Dwyer T., Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-43. doi: 10.1016/S0140-6736(19)30237-5.
  18. Drner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393:2344-58. doi: 10.1016/S0140-6736(19)30546-X.
  19. Соловьев С.К., Асеева Е.А., Попкова Т.В. и др. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. [Soloviev S.K., Aseeva E.A., Popkova T.V. et al. Systemic lupus erythematosus: new horizons for diagnosis and therapy. Nauchno-prakticheskaya revmatologiya. 2020;58(1):5-14. (In Russ.)].
  20. Laurie S., Reimold A.M. Research and therapeutics -traditional and emerging therapies in systemic lupus erythematosus. Rheumatol. (Oxford). 2017;56(Suppl. 1):i100-13.
  21. Fassbinder T., Saunders U., Mickholz E., et al. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus. Arthr Res Ther. 2015;17:92. doi: 10.1186/s13075-015-0603-8.
  22. Mok C.C. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12(4):221-34. Doi: 10.1038/ nrrheum.2015.174.
  23. Rainsford K.D., Parke A.L., Clifford-Rashotte M., Kean W.F. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacol. 2015;23:231 69. doi: 10.1007/s10787-015-0239-y
  24. James J.A., Kim-Howard X.R., Bruner B.F., et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16:401-9. doi: 10.1177/0961203307078579.
  25. Abarientos C., Sperber K., Shapiro D.L., et al. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Safety. 2011;10:705-14. Doi:10.15 17/14740338.2011.566555.
  26. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5(Suppl. 1):S4-10.
  27. Fortin PR., Abrahamowicz M., Ferland D., et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthr Rheum. 2008;59:1796-804.
  28. Pego-Reigosa J.M., Cobo-Ibanez T., Calvo-Alen J., et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthr Care Res. 2013;65:1775-85. doi: 10.1002/acr.22035.
  29. Bao H., Liu Z.H., Xie H.L., et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008;19:2001-10. Doi:10.1681/ ASN.2007121272.
  30. Liu Z., Zhang H., Liu Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Int Med. 2015;162:18-26. Doi:10.7326/ M14-1030.
  31. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Монография. Под ред. Е.Л. Насонова. М., 2011. 344 с.: ил. [Anti-B-cell therapy in rheumatology: focus on rituximab. Monograph. Ed. by E.L. Nasonov. M., 2011. 344 p. (In Russ.)].
  32. Duxbury B., Combescure C., Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22:1489-503. doi: 10.1177/0961203313509295.
  33. Цанян М.Э., Соловьев С.К., Торгашина А.В. и др. Эффективность терапии ритуксимабом у больных рефрактерной к стандартной терапии системной красной волчанкой при длительном динамическом наблюдении. Научно-практическая ревматология. 2014;52(2):159-68. [Tsanyan M.E., Soloviev S.K., Torgashina A.V. et al. The effectiveness of rituximab therapy in patients with refractory to standard therapy with systemic lupus erythematosus with long-term follow-up. Nauchno-prakticheskaya revmatologiya. 2014;52(2):159-68. (In Russ.)].
  34. Reddy V., Dahal L.N., Cragg M.S., Leandro M. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016;21:1330-38. doi: 10.1016/j.drudis.2016.06.009.
  35. Mysler E.F., Spindler A.J., Guzman R., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthr Rheum. 2013;65:2368-79. doi: 10.1002/art.38037.
  36. Dorner T., Shock A., Goldenberg D.M., Lipsky P.E. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmun Rev. 2015;14:1079-86. Doi: 10.1016/j. autrev.2015.07.013.
  37. Vilas-Boas A., Morais S.A., Isenberg D.A. Belimumab in systemic lupus erythematosus. RMD Open. 2015;1:e000011. Doi: 10.1136/ rmdopen-2014-000011.
  38. Асеева Е.А., Соловьев С.К., Меснянкина А.А., Насонов Е.Л. и др. Результаты наблюдательного проспективного исследования эффективности и безопасности белимумаба (Бенлисты®) при системной красной волчанке в реальной клинической практике. Научно-практическая ревматология. 2016;54(1):31-7.
  39. Меснянкина А.А., Соловьев С.К., Асеева Е.А., Насонов Е.Л. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9. [Mesnyankina A.A., Soloviev S.K., Aseeva E.A., Nasonov E.L. Efficiency of genetically engineered biological therapy and features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2018;56(3):302-9. (In Russ.)].
  40. Vincent F.B., Morand E.F., Schneider P., Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nature reviews. Rheumatol. 2014;10:365-73. doi: 10.1038/ nrrheum.2014.33.
  41. Duxbury B., Combescure C., Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013;22:1489-503. doi: 10.1177/0961203313509295.
  42. Samotij D., Reich A. Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review. BioMed Res Int. 2019;Article ID 8142368:17. doi: 10.1155/2019/8142368.
  43. Magro R. Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus. Ther Adv Musculoskel. Dis. 2019;11:1-9. doi: 10.1177/1759720X19874309.
  44. McCarthy E.M, Sutton E., Nesbit S., et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatol (Oxford). 2018;57(3):470-79. doi: 10.1093/rheumatology/kex395.
  45. Chavarot N.,Verhelst D., Pardon A., et al. Rituximab alone as induction therapy for membranous lupus nephritis A multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. Doi:10.1097/ MD.0000000000007429.
  46. Насонов Е.Л., Соловьев С.К. Перспективы фармакотерапии системной красной волчанки. Научно-практическая ревматология. 2014;52(3):311-21. [Nasonov E.L., Soloviev S.K. Prospects for the pharmacotherapy of systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2014;52(3):311-21. (In Russ.)].
  47. Condon M.B., Ashby D., Pepper R.J., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72:1280-86. Doi: 10.1136/ annrheumdis-2012-202844.
  48. Gracia-Tello B., Ezeonyeji A., Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci. Med. 2017;4(1):e000182. doi: 10.1136/lupus-2016000182.
  49. Sramek M., Neradil J., Veselska R. Much more than you expected: the non-DHFR-mediated effects of methotrexate. Biochim Biophys Acta Gen Subj. 2017;1861:499-503. Doi: 10.1016/j. bbagen.2016.12.014.
  50. Chan E.S.L., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthr Res. 2002;4:266-73. doi: 10.1186/ar419.
  51. Sakthiswary R., Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23(3):225-35. doi: 10.1177/0961203313519159.
  52. Насонов Е.Л. Метотрексат при ревматоидном артрите - 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33. [Nasonov E.L. Methotrexate for rheumatoid arthritis - 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya. 2015;53(4):421-33. (In Russ.)].
  53. Gansauge S., Breitbart A., Rinaldi N., Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56(6):382-85. doi: 10.1136/ard.56.6.382.
  54. Andersson J., Nagy S., Groth C.G, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunol. 1992;75(1):136-42.
  55. Mok C.C. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):429-38. Doi: 10.1016/j. berh.2017.09.010.
  56. Zhou T, Lin S., Yang S., Lin W. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther. 2019;13:857-69. doi: 10.2147/DDDT.S189156.
  57. Chen W., Tang X., Liu Q., et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44. Doi: 10.1053/j. ajkd.2010.08.036.
  58. Wang S., Li X., Qu L., et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus. 2012;21(9):1025 35. doi: 10.1177/0961203312448105
  59. Zhang H., Hu W., Xie H., et al. Randomized controlled trial of tacrolimus versus intravenous cyclophosphamide in the induction trerapy of class V plus IV lupus nephritis. J Nephrol Dialy Transplant. 2006;15(6):508-14.
  60. Mok C.C., Ying K.Y., Yim C.W., et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis. 2016;75(1):30-6. doi: 10.1136/annrheumdis-2014-206456.
  61. Li X., Ren H., Zhang Q., et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012;27(4):1467-72. doi: 10.1093/ndt/gfr484.
  62. Liu Z., Zhang H., Liu Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. doi: 10.7326/M14-1030.
  63. Sakai R., Kurasawa T., Nishi E., et al. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan. Lupus. 2018;27(2):273-82. doi: 10.1177/0961203317719148.
  64. Jesus D., Rodrigues M., da Silva J.A.P, Ins L. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis. Lupus. 2018;27(8):1358-62. doi: 10.1177/0961203318758508.
  65. Wiederrecht G., Lam E., Hung S., et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci. 1993;696:9-19. doi: 10.1111/j.1749-6632.1993. tb17137.x.
  66. Mok C.C. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:429e438. doi: 10.1016/j. berh.2017.09.010.
  67. B rsan T., Dambrin C., Freitag D.G., et al. The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl Int. 2005;17:767e71. doi: 10.1007/s00147-004-0799-z.
  68. Dooley M.A., Pendergraft III W., Ginzler E.M., et al. Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract] Arthr Rheumatol. 2016;68(Suppl. 10).
  69. Navarra S.V., Guzman R.M., Gallacher A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31. doi: 10.1016/S0140-6736(10)61354-2.
  70. Furie R., Petri M., Zamani O., et al. A phase II, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthr Rheum. 2011;63:3918-30. doi: 10.1002/art.30613.
  71. Strand V., Levy R.A., Cervera R., et al. BLISS-52 and -76 study groups. Improvements in health-related quality of life with belimumab, a B lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014; 73:838-44.
  72. Zhang F, Bae S.C., Bass D., et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355-63. Doi: 10.1136/ annrheumdis-2017-211631
  73. Guerreiro Castro S., Isenberg D.A. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther AdvMusculoskelet Dis. 2017;9(3):75 85. doi: 10.1177/1759720X17690474
  74. Stohl W., Schwarting A., Okada M., et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, doubleblind, placebo-controlled study. Arthr Rheumatol. 2017;69:1016-27. doi: 10.1002/art.40049.
  75. Doria A, Bass D., Schwarting A., et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018;27:1489-98. doi: 10.1177/0961203318777634.
  76. Lavie F., Miceli-Richard C., Ittah M., et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment:insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66(5):700-3. doi: 10.1136/ard.2006.060772.
  77. Carter L.M., Isenberg D.A., Ehrenstein M.R. Elevated serum BAFF levels are associated with rising antidouble-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthr Rheum. 2013;65(10):2672-9. doi: 10.1002/art.38074.
  78. Ehrenstein M.R., Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72. doi: 10.1038/nrrheum.2016.18.
  79. Petri M., Stohl W., Chatham W., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthr Rheum. 2008;58:2453-59. doi: 10.1002/art.23678.
  80. Wei Yu Lin, Seshasayee D., lee W.P, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthr Rheum. 2015;67(1):215-24. doi: 10.1002/art.38907.
  81. Kraaij T, Huizinga T.W., Rabelink T.J., et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatol. 2014;53:2122-24. doi: 10.1093/rheumatology/keu369.
  82. De Vita S., QuartuccioL.,Salvin S., etal. Sequential therapy with belimumab followed by rituximab in Sjo gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF:evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32(4):490-94.
  83. Меснянкина А.А., Соловьев С.К., Александрова Е.Н. и др. Двойная терапия генно-инженерными биологическими препаратами у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2016;54(3):281-88. [Mesnyankina A.A., Soloviev S.K., Alexandrova E.N. et al. Dual therapy with genetically engineered biological drugs in patients with systemic lupus erythematosus. Nauchno-prakticheskaya revmatologiya. 2016;54(3):281-88. (In Russ.)].
  84. Jones A., Muller P., Dore C.J., et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019;9( 12):e032569. Doi: 10.1136/ bmjopen-2019-032569.
  85. Larosa M., Zen M., Gatto M., et al. IL-12 and IL-23/ Th17 axis in systemic lupus erythematosus. Exp Biol Med. (Maywood). 2019;244(1):42-51. doi: 10.1177/1535370218824547.
  86. Dai H., He F., Tsokos G.C., Kyttaris V.C. IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus. J Immunol. 2017;199(3):903-10. doi: 10.4049/jimmunol.1700418.
  87. van Vollenhoven R.F., Hahn B.H., Tsokos G.C., Lipsky P., et al. Maintenance of efficacy and safety of ustekinumab through 1 year in a randomized phase II trial of patients with active systemic lupus erythematosus. Arthr Rheumatol. 2019 Nov 25. doi: 10.1002/art.41179.
  88. Насонов Е.Л, Соловьев С.К. Перспективы фармакотерапии системной красной волчанки. Научнопрактическая ревматология. 2014;52(3):311-21. https://doi.org/10.14412/1995-4484-2014-311-321
  89. Felten R., Scher F, Sagez F, et al. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des. Devel Ther. 2019; 13:1535 43. doi: 10.2147/DDDT.S170969
  90. Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. Doi:https://doi.org/10.14412/1995-4484-2019-8-16
  91. Konig N., Fiehn C., Wolf C., et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468-72. Doi: 10.1136/ annrheumdis-2016-209841.
  92. Rodero M.P, Fremond M.-L., Rice G.I., et al. JAK inhibition in STING-associated interferonopathy. Ann Rheum Dis 2016;75(12):e75-5. Doi: 10.1136/ annrheumdis-2016-210504.
  93. Hildebrand A.M., Huang S.H., Clark W.F Plasma exchange for kidney disease: What is the best evidence? Adv Chronic Kidney Dis. 2014;21:217-27. doi: 10.1053/j.ackd.2014.01.008.
  94. Pagnoux C., Korach J.M., Guillevin L. Indications for plasma exchange in systemic lupus erythematosus in 2005. Lupus. 2005;14:871-77. doi: 10.1191/0961203305lu2174rr.
  95. Walters G. Role of therapeutic plasmapheresis in ANCA -associated vasculitis. Pediatr Nephrol. 2016;31:217-
  96. doi: 10.1007/s00467-014-3038-6.
  97. Frausova D., Hruskova Z., Lanska V., et al. Longterm outcome of patients with ANCA-associated vasculitis treated with plasma exchange: A retrospective, single-centre study. Arthr Res Ther. 2016;18:168. doi: 10.1186/s13075-016-1055-5.
  98. Li Q.Y., Yu F, Zhou F.D., Zhao M.H. Plasmapheresis is associated with better renal outcomes in lupus nephritis patients with thrombotic microangiopathy: A case series study. Med. (Baltimore) 2016;95:e3595. doi: 10.1097/MD. 0000000000003595.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies